JiadeLi and CoreMed Receive SSE IPO Acceptance, Unveil Advanced Product Portfolios in Prospectus

According to the Zhicheng Finance APP, on November 6, the Shanghai Stock Exchange disclosed that the IPO applications of Quanzhou Jiadel Electron Material Co., Ltd. (Jiadel) and Shenzhen Core Medical Technology Co., Ltd. (Core Medical) have been accepted by the Shanghai Stock Exchange.

According to the prospectus,JiadeliIt is a national-level specialized and new "little giant" enterprise and a high-tech enterprise that focuses on the research, development, production, and sales of BOPP electrical films. With over 20 years of deep cultivation in the BOPP electrical film field, it has a rich and highly competitive product reserve portfolio. Through long-term technological research and development and process accumulation, the company has continuously made breakthroughs in key technical indicators such as ultra-thinness, high-temperature resistance, and high-voltage resistance. Currently, across different specification product series, it can achieve stable mass production of landmark products such as 1.9µm ultra-thin film, 125°C ultra-high temperature resistant film, 900V ultra-thin film, and 2,000V special pulse film. These products are widely used in emerging fields such as new energy vehicles, renewable energy, and flexible direct current transmission and transformation.

The prospectus shows,Core MedicalShenzhen Core Medical Technology Co., Ltd. is an innovative medical device company dedicated to providing more comprehensive, innovative, and high-quality artificial heart products. As of the date of the prospectus, the company has developed a portfolio of 5 implantable and 6 interventional artificial heart products, among which one implantable product has been commercialized, two interventional products are in the registration approval stage, and several artificial heart products are in clinical trials. A total of three core products from the abovementioned have been included in China’s special review process for innovative medical devices, including the implantable left ventricular assist system Corheart.^®6. Implantable Dual-Heart Assist System DuoCor^®2 and Interventional Ventricular Assist System CorVad^®4.0/6.0 series, ranked first in the number of products in China's artificial heart field.